Get the latest tech news
Promise Bio exits stealth backed by Pfizer and AstraZeneca
The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune diseases.
Tel Aviv-based Promise Bio has developed a cloud-based AI platform that can spot different Post-Translational Modifications (PTMs) in proteins from a single blood sample. His wife, Gal Noyman-Veksler, a partner at VC LionBird, came home one day in 2021 and told him that she had met Yifat Merbl, a senior scientist at the Weizmann Institute of Science in Israel, that was looking to spinout the computational biology tech she was working on. Veksler said that Promise Bio has gotten inbound interest form researchers and drug developers targeting other conditions like neuro indications, but the team is focused on autoimmune disorders for now — which impact an estimated .
Or read this on TechCrunch
